Capital International Investors Raises Holdings in Insmed, Inc. $INSM

Capital International Investors grew its holdings in Insmed, Inc. (NASDAQ:INSM) by 1.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,553,853 shares of the biopharmaceutical company’s stock after buying an additional 74,994 shares during the quarter. Capital International Investors’ holdings in Insmed were worth $1,087,830,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after acquiring an additional 2,291,328 shares during the period. Norges Bank purchased a new stake in shares of Insmed during the 2nd quarter worth $194,728,000. Artisan Partners Limited Partnership boosted its position in shares of Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares in the last quarter. Orbis Allan Gray Ltd acquired a new position in shares of Insmed during the 2nd quarter worth $153,389,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Insmed during the 2nd quarter worth $108,898,000.

Insmed Price Performance

Shares of NASDAQ INSM opened at $143.13 on Tuesday. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The company’s 50-day moving average price is $157.92 and its 200 day moving average price is $165.91. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The stock has a market cap of $30.85 billion, a price-to-earnings ratio of -22.33 and a beta of 1.13.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the previous year, the firm posted ($1.32) EPS. The business’s revenue was up 152.6% on a year-over-year basis. As a group, research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INSM has been the subject of several recent analyst reports. Bank of America set a $203.00 price objective on shares of Insmed in a research note on Thursday, December 18th. Stifel Nicolaus set a $205.00 target price on shares of Insmed in a research report on Thursday, February 19th. Cantor Fitzgerald lifted their price target on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Royal Bank Of Canada boosted their price target on Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Finally, Guggenheim lowered their price target on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $207.52.

Insider Buying and Selling

In related news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the transaction, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the sale, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 189,651 shares of company stock valued at $31,784,545. Corporate insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.